BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -82.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -82.27% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | -82.27% | |||
| SG&A Expenses | 4.36% | 3.19% | |||
| Depreciation & Amortization | 61.15% | -13.50% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.95% | 17.26% | |||
| Operating Income | -8.06% | -27.66% | |||
| Income Before Tax | 21.95% | -16.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.95% | -16.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.95% | -16.23% | |||
| EBIT | -8.06% | -27.66% | |||
| EBITDA | -8.13% | -27.91% | |||
| EPS Basic | 21.21% | -13.79% | |||
| Normalized Basic EPS | 23.81% | -16.67% | |||
| EPS Diluted | 21.21% | -13.79% | |||
| Normalized Diluted EPS | 23.81% | -16.67% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||